Royalty Pharma (RPRX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Royalty Pharma

    NASDAQ: RPRX · Real-Time Price · USD
    36.07
    -0.42 (-1.15%)
    At close: Oct 03, 2025, 3:59 PM
    36.00
    -0.19%
    After-hours: Oct 03, 2025, 06:22 PM EDT

    Royalty Pharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
    Revenue
    		 2.31B 2.26B 2.26B 2.27B 2.24B 2.24B 2.35B 2.32B 2.36B 2.36B 2.24B 2.25B 2.26B 2.28B 2.29B 2.29B 2.24B 2.19B
    Cost of Revenue
    		 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Gross Profit
    		 2.31B 2.26B 2.26B 2.27B 1.7B 1.16B 596.07M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Operating Income
    		 1.84B 1.9B 1.29B 1.54B 960.19M 939.4M 1.49B 396.6M 437.37M 566.32M 307.06M 943.14M 1.05B 1.42B 1.43B 1.59B 1.8B 1.46B
    Interest Income
    		 46.16M 51.22M 47.34M 44.81M 50.73M 63.01M 72.29M 109.64M 100.24M 85.51M 78.33M 45.12M 43.35M 46.47M 53.53M 64.11M 53.43M 42.12M
    Pretax Income
    		 1.66B 1.77B 1.33B 1.71B 1.03B 1.19B 1.7B 372.47M 470.81M 611.07M 230.06M 893.76M 895.15M 1.21B 1.24B 1.55B 1.96B 1.75B
    Net Income
    		 1.02B 1.09B 858.98M 1.15B 673.24M 798.86M 1.13B 184.41M 254.95M 331.83M 42.83M 506.82M 466.1M 602.37M 619.73M 782.92M 971.62M 972.92M
    Selling & General & Admin
    		 414.79M 289.72M 236.67M 228.26M 228.78M 221.71M 249.75M 263.79M 257.25M 261.46M 227.3M 200.24M 198.13M 191.21M 182.83M 186.78M 188.93M 186.81M
    Research & Development
    		 352M 52M 2M 2M 52M 52M 52M 102M 77M 77.11M 177.11M 230.43M 295.43M 297.94M 200.08M 104.04M 18.64M 21.29M
    Other Expenses
    		 -302.11M 21.72M 732.46M 491.91M 996.65M 1.03B 560.66M 1.56B 1.59B 1.45B 1.53B 873.37M 711.94M 368.2M 475.84M 403.73M 232.1M 523.14M
    Operating Expenses
    		 464.67M 363.44M 971.13M 722.18M 1.28B 1.3B 862.4M 1.93B 1.92B 1.79B 1.93B 1.3B 1.21B 857.35M 858.75M 694.55M 439.66M 731.24M
    Interest Expense
    		 266.2M 246.54M 225.51M 207.01M 186.53M 184.47M 187.19M 186.89M 187.83M 187.85M 187.96M 187.98M 185.33M 175.79M 166.14M 157.01M 144.13M 140.89M
    Selling & Marketing Expenses
    		 n/a n/a n/a -185K -185K -185K -185K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Cost & Expenses
    		 464.67M 363.44M 971.13M 722.18M 1.28B 1.3B 862.4M 1.93B 1.92B 1.79B 1.93B 1.3B 1.21B 857.35M 858.75M 694.55M 439.66M 731.24M
    Income Tax Expense
    		 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 432.29M 425.59M 445.99M 446.04M 451.02M 448.62M 446.57M 448.44M 450.4M 445.61M n/a 439.29M 436.32M 433.96M n/a 428.23M 409.34M 389.76M
    Shares Outstanding (Diluted)
    		 562M 578M 589M 593M 596.91M 597.48M 446.57M 601.14M 605.86M 607.25M n/a 607.23M 607.21M 607.2M n/a 607.17M 607.16M 607.15M
    EPS (Basic)
    		 2.32 2.48 1.93 2.57 1.51 1.79 2.54 1.43 1.59 1.78 1.14 1.14 1.06 1.44 1.50 1.94 2.49 1.50
    EPS (Diluted)
    		 1.73 1.91 1.51 2.27 1.51 1.78 2.53 1.42 1.58 1.78 1.14 1.14 1.06 1.44 1.50 1.94 2.49 1.50
    EBITDA
    		 1.93B 2.02B 1.56B 1.92B 1.22B 1.37B 1.89B 559.36M 658.64M 798.92M 423.69M 1.09B 1.1B 1.41B 1.43B 1.73B 2.12B 1.92B
    EBIT
    		 1.93B 2.02B 1.56B 1.92B 1.22B 1.37B 1.89B 559.36M 658.64M 798.92M 418.02M 1.08B 1.08B 1.39B 1.41B 1.71B 2.1B 1.89B
    Depreciation & Amortization
    		 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 5.67M 11.47M 17.26M 23M 23M 23M 23M 23M

    Add to Watchlist